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Objectives: Reporting bias potentially threatens the validity of results in health technology assessment (HTA) reports. Our study aimed to explore policies and practices of HTA
agencies regarding strategies to include previously unpublished data in their assessments, focusing on requests to industry for unpublished data.
Methods: We included international HTA agencies with publicly available methods papers as well as HTA reports. From the methods papers and recent reports we extracted
information on requests to industry and on searches in trial registries, regulatory authority Web sites and for conference abstracts.
Results: Eighteen HTA agencies and seventy-three reports were included. Agencies’ methods papers showed variability regarding requests to industry (requests are routinely carried
out in seven cases, not mentioned in six, at the discretion of HTA authors in three, and based on manufacturer applications in two), which were reflected in the reports investigated.
As reporting of requests was limited, it often remained unclear whether unpublished data had been received. Searches in trial registries, at regulatory authorities or for conference
abstracts are described as a routine or optional part of the search strategy in the methods papers of 9, 11, and 8 included agencies, respectively. A total of 52 percent, 39 percent,
and 16 percent of reports described searches in trial registries, at regulatory agencies, and hand searching of conference proceedings.
Conclusion: International HTA agencies currently differ considerably in their efforts to address the issue of unpublished data. Requests to industry may constitute one strategy to
access and include unpublished data, while agencies can learn from each other concerning successful practice.
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Evidence on Reporting Bias
Over the last few decades, evidence has been accumulating on
the existence of reporting biases in the medical literature which
“arise when the dissemination of research findings is influenced
by the nature and direction of results” (p. 298 (1)). A recent
overview found examples of reporting bias in 50 different inter-
ventions and procedures in the fields of pharmacology, surgery,
diagnostics, and prevention, thus demonstrating that this phe-
nomenon poses a major problem in the assessment of health
care interventions (2). The best known form of reporting bias is
publication bias, defined as “the publication or nonpublication
of research findings, depending on the nature and direction of
the results” (p. 298 (1)). However, even in published studies,
subsets of the original outcomes or analyses may be selectively
reported (outcome or analysis reporting bias) (3).
The authors thank Kay Dickersin, Milo Puhan, and Annette Zentner for their contributions during
the design phase of the study; Elke Hausner and Natalie McGauran for their comments on a draft
version of this paper; and Natalie McGauran for editorial support. The views expressed in this
article are those of the authors and do not necessarily represent those of the Institute for Quality
and Efficiency in Health Care or the University of Technology, Berlin.
Challenge for HTA Agencies
Reporting bias tends to overestimate benefits and underestimate
harms of health care interventions, thus leading to potentially
biased conclusions in systematic reviews and health technol-
ogy assessment (HTA) reports (2;4). This was illustrated by
a recent assessment of reboxetine by the German HTA agency
IQWiG (Institute for Quality and Efficiency in Health Care): the
inclusion of data from ten trials, which had previously been un-
published or incompletely published and were provided by the
manufacturer only after considerable public pressure, had a sig-
nificant impact on the assessment’s results. IQWiG’s conclusion
that reboxetine is “overall an ineffective and potentially harm-
ful antidepressant” (p. 8 (5)) stood in contrast to the findings
of several earlier systematic assessments that did not combine
all of the existing evidence from clinical trials (6), and ulti-
mately led to the exclusion of reboxetine from reimbursement in
Germany.
Data Accessible to HTA Agencies
Legislation requires manufacturers to grant regulatory author-
ities such as the U.S. Food and Drug Administration (FDA)
comprehensive access to both published and unpublished data
for the approval process (e.g., (7)). However, manufacturers are
not generally obliged to provide all of the relevant data to HTA
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agencies for post-approval evaluations (8). Health policy deci-
sions, for example, on the reimbursement of drugs, are therefore
often based mainly on publicly available information with the
potential insufficiencies described above (8–10).
One way of overcoming the selective or nonpublication of
studies is their registration in public databases: in 2004, the
International Committee of Medical Journal Editors specified
that registration in a public trial registry was a prerequisite
for a study’s publication (11). In response to public concerns
about reporting biases and to legal proceedings (the paroxetine
case (12)), several individual pharmaceutical companies, aswell
as industry associations such as the Pharmaceutical Research
and Manufacturers of America (PhRMA), installed their own
registries. In 2007, the FDAAmendments Act made registration
and public posting of all applicable clinical trials in the registry
ClinicalTrials.gov compulsory for the United States (13). In
Europe, the publicly accessible EU Clinical Trials Register was
launched only recently (March 2011) and contains information
on phase 2–4 adult clinical trials and any pediatric clinical trial
carried out in the European Union from 2004 onward (14).
However, existing regulations for trial registration have several
loopholes, particularly as older drugs, although widely used in
clinical practice, are not covered (8;15).
Other strategies used to identify potentially relevant unpub-
lished studies or data include searching for regulatory authority
Web sites as well as conference abstracts, as approximately half
of trials reported in conference abstracts are never fully pub-
lished, and publication is associated with positive results (16).
However, it has been argued that publicly available sources do
not necessarily contain all relevant clinical trial results for a
given healthcare intervention, and that access to these results is
still insufficient (13).
As publication is not a dichotomous event, but rather a
continuum (17), the distinction between “published” and “un-
published” is not always clear cut (2). In our study, we use the
term “published” to refer to articles published in peer-reviewed
journals and the term “unpublished” to refer both to publicly
inaccessible data owned by industry or study authors and to
“gray literature,” that is, studies not published in peer-reviewed
journals but nevertheless publicly available in sources such as
trial registries, regulatory authorities or published as conference
abstracts.
Aim of Our Study
To the best of our knowledge, no detailed analysis is currently
available as to how international HTA agencies address the
challenge of unpublished data. On the basis of an analysis of
publicly available methods papers and HTA reports, the aim
of our study was, therefore, to provide an overview of cur-
rent policies and practices with regard to searching for, in-
cluding and reporting of unpublished data. Our primary in-
terest was to explore whether and how HTA agencies carry
out requests to industry to include data in their assessments
that are not publicly available at all. We also explored to what
extent alternative strategies are pursued to identify grey litera-
ture from trial registries, regulatory authorities and conference
abstracts.
METHODS
Eligible HTA Agencies and Documents
We analyzed two different data sources: “methods papers,” that
is, documents describing the HTA organizations’ methods for
assessing the effectiveness of interventions, and “HTA reports,”
that is, full assessments of a health technology or focused as-
sessments of drugs for reimbursement and pricing decisions.We
aimed for a broad sample to capture current practice in the HTA
community and therefore identified international HTA agencies
from four different sources: (a) members of the International
Network of Agencies for Health Technology Assessment (IN-
AHTA) as of December 2010, (b) partners in the European Net-
work forHealth TechnologyAssessment (EUnetHTA) project as
of December 2010, (c) nonprofitmembers inHealth Technology
Assessment international (HTAi) as of May 2011, and (d) HTA
agencies included in comparative analyses published in the In-
ternational Journal of Technology Assessment in Health Care in
the years 2009 and 2010. Eligible agencies were those that pro-
duced HTA reports and for which we were able to identify both
eligiblemethods papers andHTA reports in English, German, or
French (for inclusion and exclusion criteria see Supplementary
Table 1: http://dx.doi.org/10.1017/S026646231300072X).
Data Collection, Extraction, and Analysis
We searched all Web sites of potentially eligible agencies at
the beginning of 2011, both to check whether they are di-
rectly involved in HTA by either commissioning or conducting
assessments and to identify methods papers as well as HTA
reports. We contacted agencies between February and May
2011 to verify the information obtained online and confirm
the completeness and currentness of the documents retrieved.
We did not contact agencies where the Web site clearly indi-
cated that they are not involved in HTA production or where
insufficient information in English, French, or German was
available.
Methods Papers. We included methods papers developed by the re-
spective agencies that were publicly available and described
methods for assessing the effectiveness (i.e., not only cost-
effectiveness) of drug or nondrug therapeutic interventions. We
included more than one methods paper if they had different
scopes, yet only those for which eligible reports were also pub-
licly available. If further documents explicitly addressing the
inclusion and handling of unpublished data were available, they
were also included in the analysis.
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INAHTA
members 
n = 51
EUnetHTA partner 
organizations
n = 42
HTAi non-profit 
members
n = 60
IJTAHC
2009-2010  
n = 72
Agency pool
n = 121
Duplicate organizations
n = 104
HTA agencies 
included in analysis
n = 18
Excluded organizations
n = 103
 
 - Agency ceased to exist (n = 2)
 - Insufficient information available (including language of   
   Web site) (n = 50)
 - No production of HTA (n = 15)
 - Language (methods papers, reports) (n = 12)
 - No own methods paper identified (n = 18)
 - Reports not publicly available (n = 5)
 - No reports on drug or non-drug therapeutic interventions (n = 1)
Figure 1. Flow chart of selection of HTA agencies (May 2011).
HTA Reports. We included HTA reports that were publicly avail-
able in full (i.e., not only in summary) and reported a sys-
tematic evaluation (i.e., based on a search for literature in at
least two sources) of the effectiveness of drug or nondrug
therapeutic interventions from January 2006 onward. We ex-
cluded reports that (i) were commissioned by another agency
that was also included in our sample, (ii) were based solely
on secondary publications (e.g., “reviews of reviews” that did
not include primary studies), or (iii) were draft versions. We
included the three most recent reports on both drugs and non-
drug therapeutic interventions or fewer if less than three were
available.
To reduce the heterogeneity between reports and due to lim-
ited resources, we did not examine documents (neither methods
papers nor HTA reports) reporting the evaluation of diagnostic
procedures or population-based preventive interventions. In ad-
dition, for agencies producing different types of documents, we
restricted our analysis to one type (e.g., to multiple technology
assessments for NICE documents) to reduce the complexity of
the analysis.
We developed and pilot-tested sheets to extract infor-
mation from methods papers and HTA reports. Informa-
tion was extracted by one person (JK) and checked by a
second (DP) for the categories depicted in Supplementary
Table 2, which can be viewed online at http://dx.doi.org/
10.1017/S026646231300072X. Disagreements were solved by
discussion and by consulting the original documents again.
We provide a qualitative analysis of information obtained from
methods papers to show the range of different approaches cur-
rently in place at the agencies in our sample and descriptive
statistics for the analyses of HTA reports.
RESULTS
Agencies Included in Our Sample
A total of 121 agencies were potentially eligible and eighteen
fulfilled all inclusion criteria (see Figure 1). The agencies in-
cluded (see Table 1) are diverse with regard to their scope and
their role within the respective health care systems.
Methods Papers Describing Efforts to Include Unpublished Data
Methods papers published by eligible agencies varied consider-
ably regarding length (ranging from 9 to 294 pages), as well as
currentness, with the oldest documents having been published in
2000, and the newest ones published as drafts in 2011 (for a com-
plete list, see Supplementary Table 3, which can be viewed on-
line at http://dx.doi.org/10.1017/S026646231300072X). Some
of the agencies contacted informed us that the methods pa-
pers were being revised at the time of our research or no
longer reflected current practice and more recent, internal
guidance was being followed instead. However, in the ab-
sence of more up-to-date, publicly available documents, these
methods papers were still included. The documents also re-
flect the scope of the respective agency, thus being com-
prehensive or addressing exclusively the evaluation of drugs
or medical devices. Some of the documents are specific
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Table 1. Agencies Included in the Analysis and Approaches Regarding Requests to Industry
Abbreviation Agency’s name (country) Approach
AHRQ Agency for Healthcare Research and Quality (United States) 1
ASERNIP-S Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (Australia) 3
CADTH Canadian Agency for Drugs and Technologies in Health (Canada) 1
CRD Centre for Reviews and Dissemination (United Kingdom) 2
DACEHTA Danish Centre for Health Technology Assessment (Denmark) 3
DERP Drug Effectiveness Review Project (United States) 1
DIMDI Deutsches Institut fu¨r Medizinische Dokumentation und Information (Germany) 3
G-BA Gemeinsamer Bundesausschuss (Germany) 3
GO¨G Gesundheit O¨sterreich GmbH (Austria) 2
HAS Haute Autorite´ de Sante´ (France) 3
HVB Hauptverband der o¨sterreichischen Sozialversicherungstra¨ger (Austria) 3
IQWiG Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesundheitswesen (Germany) 1
KCE Belgian Health Care Knowledge Centre (Belgium) 1
LBI Ludwig Boltzmann Institut fu¨r Health Technology Assessment (Austria) 2
MSAC Medical Services Advisory Committee (Australia) 4
NICE National Institute for Health and Clinical Excellence (United Kingdom) 1
PHARMAC Pharmaceutical Management Agency (New Zealand) 4
TLV Tandva˚rds- och La¨kemedelsfo¨rma˚nsverket (Sweden) 1
Note. Explanation: 1 = Manufacturers are routinely approached; 2 = Manufacturer requests may be carried out at
the discretion of the HTA authors; 3 = Manufacturer requests are not explicitly mentioned in the methods paper; 4 =
Manufacturers (or others) file an application with their data for the product to be assessed.
The information reflects the content of the methods papers available to us at the time of our search. Note: HAS bases its
assessments on a review of the literature and dossiers from pharmaceutical companies. The only methods papers that we were
able to identify, however, did not reflect this current practice.
guidelines for the respective agencies (e.g., DERP, LBI [for
agencies’ full names, see Table 1]), while others have a
broader target audience (e.g., DACEHTA, CRD). Where guid-
ance for obtaining data was given separately for assessing
effectiveness and adverse effects (e.g., CRD, AHRQ), we lim-
ited our analysis to the former.
Requests to Industry. We found that HTA agencies pursue different
approaches concerning the question as to whether data are re-
quested from industry in the course of HTA production. These
can be grouped into four broad categories: (i) manufacturers are
routinely approached as part of the search for relevant literature
(seven agencies); (ii) manufacturer requests may be carried out
at the discretion of the HTA authors (three agencies); (iii) man-
ufacturer requests are not explicitly mentioned in the methods
paper (six agencies); (iv) manufacturers (or others) file an ap-
plication with their data for the product to be assessed (two
agencies). Differences between agencies’ approaches to a con-
siderable extent also reflect the respective national legal context
(e.g., when assessments are based on submissions by manufac-
turers instead of comprehensive searches carried out by HTA
agencies) (see Table 1).
Five of the seven agencies that routinely make requests to
manufacturers provide details of these processes in their meth-
ods papers; these are summarized in Table 2.
Conditions for accepting and including unpublished data in
reports vary between agencies. The following conditions were
addressed by at least on agency: completeness, adequate detail,
non-confidentiality, and the timely submission of the data (see
Table 3 for examples).
Few documents contain detailed guidance on how to re-
port requests to industry: CRD provides an example for the
documentation of a request, CADTH foresees requests to man-
ufacturers as a standard part of the documentation of the liter-
ature search, DERP explicitly states that companies providing
dossiers should be accounted for in the results section of the re-
port, and IQWiG also states that requests to industry have to be
documented in the reports. NICE publishes a list of consultees
on its Web site. Several agencies (e.g., GO¨G, KCE) state that
the literature search has to be documented with enough detail
to allow reproduction, without explicitly addressing requests to
industry.
Equally, only a few methods papers in our sample provide
explicit guidance on how to report previously unpublished data
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Table 2. Standardized Formats for Requests to Industry
AHRQ
Addressee: Manufacturers of products under review (drugs, devices or other products for which a manufacturer can be identified)
Content of requests: Scientific Information Packets containing
- information on products available from the product label
- information on published and unpublished studies concerning the product
Process details: Requests are managed by the Scientific Resource Center for AHRQ on behalf of the Evidence-based Practice Centers (EPCs) “to ensure consistency in
the way Scientific Information Packets (SIPs) are requested and to ensure transparency by eliminating contact between the EPC conducting the
review and the manufacturers of products being reviewed”.
DERP
Addressee: Pharmaceutical companies that manufacture any drug included in an individual report
Content of requests: Dossiers containing
- published studies (a list of citations for all relevant published studies of drugs licensed by the respective company)
- unpublished studies (trials or observational designs; with information on, e.g., study identifier, design, indication, patient population
description, inclusion & exclusion criteria, treatment of interest and all comparisons, outcomes measured, results; sufficient amount
of details on methods to allow assessment of study quality)
- unpublished, supplementary data for published clinical studies (e.g., additional details about study methods, additional outcomes, and
results of additional subgroup analyses)
- a copy of the most recent product label
Process details: Requests are managed by the Medical Director for DERP, Center for Evidence-based Policy. As all information submitted may be made available to
the public, all statements of confidentiality are considered “null and void”.
IQWiG
Addressee: Manufacturers of the technology under review
Content of requests: For drugs, a 2-step procedure is applied:
- 1) complete list of all trials carried out with the drug under assessment from the manufacturer
- 2) detailed request on the basis of 1) for unpublished studies or for additional, unpublished information on published studies
Process details: Before submission of data, an agreement is made between IQWiG and the manufacturer involved specifying the submission process, the
requirements for documents to be submitted (e.g., information provided should comply with CONSORT), and their confidential and
non-confidential components. If a manufacturer does not agree to this contract (especially with regard to the complete transfer of all information
requested) or does not completely transfer the information requested despite this contract, no further requests are made to this manufacturer.
NICE
Addressee: Manufacturers and sponsors (organizations that market the technology under license) of the technology under review
Content of requests: Submissions, i.e., a “concise, comprehensive and structured report of all relevant information (published and unpublished) for an appraisal”,
containing
- a complete list of all studies on the technology within the indication (i.e., studies may be sponsored by manufacturers or sponsors or known
to them; NICE may request further information on studies included in the list)
- a main document including, amongst other things, the aims of treatment, approved indications and an assessment of clinical effectiveness
- appendices containing supporting information for data and analyses and the excluded evidence
Process details: At the start of a project, manufacturers and sponsors are invited to take part in the appraisal as consultees. Consultees have at least 14 weeks to
prepare their submissions which are then forwarded in full to the independent academic group preparing the evidence assessment report for NICE.
in HTA reports: DERP provides complete copies of dossiers to
the public upon request once the report is published. IQWiG
foresees the possibility to publish short summaries of previ-
ously unpublished studies in its reports, as well as any addi-
tional relevant unpublished data. The methods papers of both
agencies point out that all previously unpublished data included
in the analyses are reported. If a submission to NICE contains
previously unpublished confidential information, the manufac-
turer has to provide a second version with the confidential
information removed, which is then published on the NICE
Web site as a supplementary document together with the as-
sessment. For previously unpublished trials, NICE requests a
structured abstract for public disclosure. Information that has
been submitted in confidence is removed from the actual HTA
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Table 2. Continued.
TLV
Addressee: Companies concerned by a pharmaceutical reimbursement review
Content of requests: Submission containing
- general information on the drug (e.g., administration form, dosage)
- information regarding the indication (e.g., average treatment time)
- information regarding medical effects: information on the “most important and well-executed studies” that have been conducted on the
medicines (information for each of these studies in a table format, including primary and secondary effect measure, effect of treatment
[intention to treat and per protocol analysis], losses to follow up etc.); summary of the medical effect of treatment based on these studies;
summary of the effect of treatment on the patient’s quality of life and life expectancy; advantages of the medicine regarding side effects
compared to other medicines in this class of pharmaceuticals; known variations in the medical effect of the medicine (e.g., in respect to
patients’ sex and age)
- information regarding cost-effectiveness
Process details: When commencing the review of a therapeutic group, the companies responsible for marketing drugs in this group are notified by the TLV. In this
context, they are requested to submit information on, amongst other things, the clinical use of and cost-effectiveness of the drug or drugs
marketed by the company by filling in a standard form within 8 weeks.
Note. The information reflects the content of the methods papers that were available to us at the time of our search (see Supplementary Table 3 for a full list of references).
Table 3 Conditions for the Acceptance of Unpublished Data (Examples)
Completeness:
IQWiG has an agreement with manufacturers containing an obligation for complete submission of all relevant data. NICE requires manufacturers and sponsors to sign a
statement declaring that all relevant material has been disclosed, and PHARMAC requests a declaration that all known unpublished clinical trials have been disclosed.
Adequate detail:
DERP requests sufficient amount of detail on methods of unpublished studies to allow for adequate assessment in order to include their data in the report. IQWiG requests
companies to comply with the CONSORT statement when submitting information. PHARMAC allows abstracts and posters to be used by manufacturers in their applications only
“as references to update information after the primary analyses or any analyses of secondary outcomes not detailed in the published report”, if they are adequately detailed.
Non-confidentiality:
DERP and IQWiG only accept data for inclusion in their analysis that may be made public; others (KCE, NICE, PHARMAC) also accept – under certain circumstances – data that
are submitted in (either academic or commercial) confidence.
Timely submission of data:
DERP specifies that unpublished data or studies cannot be submitted by pharmaceutical companies after the deadline for the dossier process (e.g., not via the public commenting
process for draft reports).
Note. The information reflects the content of the methods papers available to us at the time of our search (see Supplementary Table 3 for a full list of references).
report by blackening the relevant passage. Several agencies
(e.g., PHARMAC, MSAC, TLV) point out that the respective
legal requirements concerning the disclosure of confidential in-
formation apply.
Searches in Publicly Available Sources. Trial registries, regulatory au-
thorities and conference abstracts all seem to play a simi-
lar role as additional sources: routine or optional searches
in these sources are described in the methods papers
of 9, 11, and 8 of eighteen agencies, respectively (see
Supplementary Table 4, which can be viewed online at
http://dx.doi.org/10.1017/S026646231300072X). Although the
distinction between routine and optional parts of the literature
search is not always clear cut, it seems that searching for confer-
ence abstracts is less often defined as a routine element. Table 4
depicts options for searching in these sources that we identified
across agencies.
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Table 4. Options for Searching in Publicly Available Sources
Trial registries:
- Where: ClinicalTrials.gov (www.clinicaltrials.gov); Current Controlled trials (www.controlled-trials.com); WHO International Clinical Trials Registry Platform
(www.who.int/trialsearch); Clinical Study Results (www.clinicalstudyresults.org)a and further public or commercially owned registries
- To what end: identify unpublished studies; identify additional details of published studies; identify ongoing studies; contact principle investigators for further information
Regulatory authorities:
- Where: FDA (Medical and Statistical Reviews); EMA (European Public Assessment Reports) and further national authorities
- To what end: compare data from regulatory documents with results reported in respective publications to verify or find additional data; identify unpublished studies; compare
results from published and unpublished studies
Conference abstracts:
- Where: specialized databases; conference proceedings of selected meetings via hand searching
- To what end: identify studies that are not (yet) formally published in a peer-reviewed journal or indexed by electronic databases; compare preliminary data from abstracts with
formally published results to check for possible inconsistencies or find additional data; contact abstract authors for full reports
Note. The information reflects the content of the methods papers available to us at the time of our search (see Supplementary Table 3 for a full list of references).
a: This registry which was set up by PhRMA is no longer available.
HTA Reports Describing Efforts to Include Unpublished Data
We identified seventy-three HTA reports published between
2006 and 2011 (thirty-three on drugs and forty on nondrug
interventions [one report assessed both drug and nondrug in-
terventions and was analyzed twice]) in our analysis. Nine of
the HTA reports in our sample assessed nondrug interventions
that do not involve the application of a medical device (for ex-
ample, psychosocial interventions for people bereaved by sui-
cide); we thus excluded them from further analyses regarding
requests to industry and searches of regulatory authority Web
sites.
Requests to Industry. Current practices described in HTA reports
broadly reflect the methods outlined in their methods papers: of
those agencies with routine requests (see above), twenty-one of
thirty-one eligible reports (68 percent) explicitly mentioned that
requests to industry were carried out. While it remained unclear
in three reports whether any response was received, eighteen
reports described the receipt of information, although in some
cases not all of the manufacturers contacted responded. Half
of these responses (n = 9) apparently yielded data previously
not publicly accessible; one explicitly stated that no additional
information had been retrieved, and for eight reports it was not
clearly described.
Of those agencies where requests to industry are at the
discretion of the HTA authors, only four of nine reports (44
percent) described a corresponding request; in all cases it re-
mains unclear whether a response was received. None of the
seventeen reports of agencies where requests to industry were
not mentioned in the methods paper described a corresponding
request.
An analysis of the extent to which previously unpublished
data were included in the statistical analyses and their possible
impact on results turned out to be unfeasible in view of this
sparse reporting.
Seven reports were included of those agencies where man-
ufacturers (or others) file an application for the product to be
assessed (HAS, MSAC, PHARMAC). While three reports of
MSAC did not include unpublished data (possibly reflecting the
fact that these reports are carried out separately from the assess-
ment of the manufacturer’s application), two of the three HAS
reports included unpublished data. Data submitted to PHAR-
MAC included slides presented at conferences and further data
submitted in confidence.
Searches in Publicly Available Sources. In thirty-eight of seventy-three re-
ports (52 percent) in our sample, trial registries were searched.
Most reports stated that this was done to identify ongoing trials,
but some also described that this served to identify both on-
going and unpublished trials. The registry most often searched
was ClinicalTrials.gov. In twenty-five of sixty-four reports (39
percent) involving the use of drugs or medical devices, regu-
latory authority Web sites (mostly the FDA) were searched to
identify further documents. In twelve of seventy-three reports
(16 percent), the literature search explicitly encompassed hand
searching of selected conference proceedings. Of the remain-
ing reports, many reported searches in specialized electronic
databases, for example, Conference Papers Index, Inside Con-
ferences or ISI Proceedings.
DISCUSSION
Policies and Practices Regarding Requests to Industry
Although the neglect of unpublished data can seriously threaten
the validity of HTA reports, international HTA agencies cur-
rently differ considerably in their efforts to address this issue,
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both with regard to the question as to whether and how industry
is asked for unpublished data and to policies concerning the re-
porting and publishing of data received. Current practices vary
according to the different policies implemented by the agencies,
where only a minority of agencies foresee routine data requests
to industry. Surprisingly, in those reports where manufacturers
were approached, the reporting of the request and of the data
retrieved was often sparse. It, therefore, often remained unclear
whether and which manufacturers were approached, whether
they provided data, and whether or where these were included
in the statistical analysis.
Alternative Strategies to Identify Unpublished Data
In approximately half of the reports, the search in bibliographic
databases was supplemented by a search in trial registries, al-
though it was often not clearly stated whether the main intent of
the search was to identify ongoing studies or studies not (yet)
published. Some HTA authors expended considerable effort in
identifying unpublished randomized controlled trials from trial
registries (e.g., (18;19)).
The handling of conference abstracts varied across agen-
cies. Abstract publications pose a serious problem for HTA
authors, as their inclusion may be important to reduce the influ-
ence of reporting bias, yet they may lack important information
(20). While many reports excluded abstracts, some HTA au-
thors decided to include studies on the basis of abstracts alone
to ensure that as much evidence as possible was included, as
long as enough information for appraising the study’s quality
was available (e.g., (19;21)). It is noteworthy in this context that
the methods papers of the HTA agencies often did not specify
how to proceed with conference abstracts once identified.
Although this was not the focus of our research, several
reports in our sample explicitly discussed the problem of pub-
lication bias or missing data (e.g., (22–25)), and some applied
strategies such as funnel plots or Egger’s weighted regression
statistics to investigate possible publication bias (e.g., (25;26)).
While many reports put considerable effort into trying to iden-
tify unpublished data by means of different strategies, some
HTA authors decided as a matter of principle not to search for
unpublished data to maintain the reproducibility of the data in-
cluded (e.g., (27)), or because unpublished data are difficult to
search for systematically and exhaustively (e.g., (28)).
POLICY IMPLICATIONS
As noted above, we did not assess the impact of requests to
industry for unpublished data on the conclusions of the HTA
reports as the current extent and quality of information did
not allow for such an analysis. The actual impact of requests to
industry therefore remains unclear for the reports in our sample.
However, as long as legislation does not require all trials to be
registered and the reporting of results in registries is incomplete
(29), there are strong arguments for such requests.
For those agencies or research groups that consider carry-
ing out requests to industry in the future, some lessons may
be learned from those agencies that already routinely do so.
As some methods papers highlight, it is important to ensure
that all relevant unpublished studies are disclosed upon request
(e.g., by requesting corresponding declarations from manufac-
turers): if data were provided selectively, this would possibly
even increase reporting bias. Standardized request forms fol-
lowing CONSORT guidelines (30) are a way to facilitate re-
quests to prevent selective reporting; ideally, full study reports
should be made available upon request. Efforts should also be
made tomake data provided bymanufacturers publicly available
as soon as possible to ensure that assessments are transparent
and the ensuing decisions open to scrutiny (31).
Given the sparse reporting of requests to industry found in
many of the reports assessed, it would be desirable to develop
reporting standards for such requests and for the information
they yield.Although reporting guidelines for systematic reviews
require all data sources to be stated (32), detailed guidance for
reporting requests to industry is currently lacking. We sug-
gest that these should include the manufacturers approached,
whether they provided data and the publication status of these
data (see also (33)).
However, some reports in our sample (e.g., (23;34)), as
well as further examples such as the reboxetine case (5) or the
Cochrane Review on Tamiflu (35), show that routine inquiries
alone are often insufficient, and despite considerable persistence
and investment of resources, all relevant data may not always
be provided, as in the case of Tamiflu (6;36).
Ideally, requests to industry will be made superfluous in
the future by legislative measures that guarantee HTA agencies
access to relevant data, as already implemented for early benefit
assessments of drugs in Germany (37). A further groundbreak-
ing initiative in the area of drug assessments is EMA’s new pol-
icy of releasing marketing authorization documents on request
(e.g., clinical study reports), after the decision-making process
for the application of the drug in question is finalized (38). This
policy has been legally challenged: in spring 2013, the General
Court, as a result of complaints filed by two pharmaceutical
companies, issued a temporary injunction ordering EMA not to
provide any documents until a final ruling is given (39). Despite
this, EMA is planning proactive publication of such information
depending on the type of data (40). For nondrug interventions,
however, the road to full availability of relevant data seems to
be much longer. Initiatives to promote the prospective public
registration of studies and disclosure of data (e.g., (41)) may,
therefore, remainmore important for studies evaluatingmedical
devices or other nondrug interventions.
Strengths and Weaknesses of Our Study
We aimed to create a comprehensive and systematic approach
for identifying HTA agencies to obtain an unbiased picture
of the HTA community. The analysis of both methods papers
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and recent HTA reports allowed capturing not only the policies
specified by the agencies, but also actual practices.
Challenges we encountered were the considerable inter-
twining of agencies in their work (i.e., mutual commissioning
of reports or mutual use of methods papers), the fact that sev-
eral HTA agencies produce different types of documents, and
difficulties in always clearly distinguishing between “real” HTA
reports and assessments triggered bymanufacturer applications.
Our study has some limitations. Approximately a quarter
of nondrug interventions assessed in the HTA reports of our
sample did not involve the application of amedical device so that
manufacturers could not be contacted.We did not systematically
evaluate whether in these cases other possible owners of data,
e.g., research groups at universities, were contacted. Selective
publication of studies, however, may be equally (or even more)
prevalent in academic research, especially with regard to study
designs other than clinical trials. A challenge in the evaluation
of interventions not commercially owned is that it is less clear
who may have carried out studies or who may be in possession
of the data, and the diversity of relevant parties in this field may
make requests difficult.
In addition, our analysis, which was exploratory in nature,
was restricted to information available in publicly available doc-
uments, and, despite our efforts, we may have failed to identify
all relevant documents. Some methods papers may also not re-
flect current policies, as indicated by some of the respondents
to our inquiries. In the absence of other information available,
we treated methods papers equally, regardless of considerable
differences with regard to their comprehensiveness and their
currentness. As the consideration of reporting bias in HTA has
changed over time, differences between methods papers in this
regard may also be related to the time at which they were writ-
ten. Inevitably, our study does not reflect current activities or
discussions at the HTA agencies that are yet unconsidered in
official documents. Thus, future research could strive for a more
extensive participatory approach to expand our knowledge on
strategies identified in our study and agencies’ experiences.
CONCLUSIONS
It seems self-evident that HTA reports influencing health care
decisions for millions of patients should be based on all rele-
vant data. To different extents, HTA agencies search trial reg-
istries, regulatory authorities’ public documents or conference
abstracts to identify studies and data not (yet) published in peer-
reviewed journals. In future, HTA agencies should be guaran-
teed comprehensive access to relevant data either by compul-
sory registration of study protocols and comprehensive results
in public trial registries or by being granted access to clinical
study documents submitted to regulatory authorities. Until then,
requests to industry may represent one strategy to access and
include unpublished data, while agencies can learn from each
other concerning successful practice. Furthermore, the devel-
opment of reporting standards for such requests and for data
obtained from manufacturers would help to improve the trans-
parency of HTA reports.
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